These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 38296700)

  • 21. Emerging Streptococcus pneumoniae Strains Colonizing the Nasopharynx in Children After 13-valent Pneumococcal Conjugate Vaccination in Comparison to the 7-valent Era, 2006-2015.
    Kaur R; Casey JR; Pichichero ME
    Pediatr Infect Dis J; 2016 Aug; 35(8):901-6. PubMed ID: 27420806
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serotype distribution of Streptococcus pneumoniae and potential impact of pneumococcal conjugate vaccines in China: A systematic review and meta-analysis.
    Chen K; Zhang X; Shan W; Zhao G; Zhang T
    Hum Vaccin Immunother; 2018 Jun; 14(6):1453-1463. PubMed ID: 29451838
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Streptococcus pneumoniae serotype distribution in Vojvodina before the introduction of pneumococcal conjugate vaccines into the National Immunization Program.
    Petrović V; Šeguljev Z; Ristić M; Djekić-Malbaša J; Radosavljević B; Medić D; Mihajlović-Ukropina M; Hadnadjev M; Gajic I; Opavski N
    Srp Arh Celok Lek; 2016; 144(9-10):521-6. PubMed ID: 29653038
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effectiveness of a 3 + 0 pneumococcal conjugate vaccine schedule against invasive pneumococcal disease among a birth cohort of 1.4 million children in Australia.
    Gidding HF; McCallum L; Fathima P; Moore HC; Snelling TL; Blyth CC; Jayasinghe S; Giele C; de Klerk N; Andrews RM; McIntyre PB;
    Vaccine; 2018 May; 36(19):2650-2656. PubMed ID: 29627233
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The 13-valent pneumococcal conjugate vaccine (PCV13) does not appear to provide much protection on combined invasive disease due to the six PCV13 non-PCV7 serotypes 1, 3, 5, 6A, 7F, and 19A in Kuwait during 2010-2019.
    Mokaddas E; Syed S; Albert MJ
    Hum Vaccin Immunother; 2021 Nov; 17(11):4661-4666. PubMed ID: 34435932
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Invasive pneumococcal disease in young children before licensure of 13-valent pneumococcal conjugate vaccine - United States, 2007.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2010 Mar; 59(9):253-7. PubMed ID: 20224541
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effectiveness of Pneumococcal Conjugate Vaccines Against Community-acquired Alveolar Pneumonia Attributable to Vaccine-serotype Streptococcus pneumoniae Among Children.
    Lewnard JA; Givon-Lavi N; Dagan R
    Clin Infect Dis; 2021 Oct; 73(7):e1423-e1433. PubMed ID: 33346348
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pneumococcal serotype evolution in Western Europe.
    Tin Tin Htar M; Christopoulou D; Schmitt HJ
    BMC Infect Dis; 2015 Oct; 15():419. PubMed ID: 26468008
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term Impact of a "3 + 0" Schedule for 7- and 13-Valent Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease in Australia, 2002-2014.
    Jayasinghe S; Menzies R; Chiu C; Toms C; Blyth CC; Krause V; McIntyre P
    Clin Infect Dis; 2017 Jan; 64(2):175-183. PubMed ID: 27986682
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical and Bacteriological Analysis of Pediatric Pneumococcal Meningitis after 13-Valent Pneumococcal Conjugate Vaccine Introduction in Japan.
    Kurihara E; Takeshita K; Tanaka S; Takeuchi N; Ohkusu M; Hishiki H; Ishiwada N
    Microbiol Spectr; 2022 Apr; 10(2):e0182221. PubMed ID: 35357224
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of the introduction of pneumococcal conjugate vaccines on serotype prevalence in Kuwait and Saudi Arabia.
    Mokaddas EM; Shibl AM; Elgouhary A; Elsobky M
    Vaccine; 2018 Oct; 36(43):6442-6448. PubMed ID: 30194003
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Potential serotype-specific effectiveness against IPD of pneumococcal conjugate vaccines V114 and PCV20 in children given a 2+1 dosing regimen.
    Ryman J; Sachs JR; Banniettis N; Weiss T; Ahsman M; Yee KL; Weaver J
    Expert Rev Vaccines; 2024; 23(1):467-473. PubMed ID: 38546743
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effectiveness of ten-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in Brazil: a matched case-control study.
    Domingues CM; Verani JR; Montenegro Renoiner EI; de Cunto Brandileone MC; Flannery B; de Oliveira LH; Santos JB; de Moraes JC;
    Lancet Respir Med; 2014 Jun; 2(6):464-71. PubMed ID: 24726406
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nasopharyngeal carriage of Streptococcus pneumoniae serotypes among children in India prior to the introduction of pneumococcal conjugate vaccines: a cross-sectional study.
    Sutcliffe CG; Shet A; Varghese R; Veeraraghavan B; Manoharan A; Wahl B; Chandy S; Sternal J; Khan R; Singh RK; Santosham M; Arora NK
    BMC Infect Dis; 2019 Jul; 19(1):605. PubMed ID: 31291902
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of the pediatric 13-valent pneumococcal conjugate vaccine on serotype distribution and clinical characteristics of pneumococcal pneumonia in adults: The Japan Pneumococcal Vaccine Effectiveness Study (J-PAVE).
    Sando E; Suzuki M; Furumoto A; Asoh N; Yaegashi M; Aoshima M; Ishida M; Hamaguchi S; Otsuka Y; Morimoto K
    Vaccine; 2019 May; 37(20):2687-2693. PubMed ID: 30975569
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The 13-valent pneumococcal conjugate vaccine (PCV13) elicits cross-functional opsonophagocytic killing responses in humans to Streptococcus pneumoniae serotypes 6C and 7A.
    Cooper D; Yu X; Sidhu M; Nahm MH; Fernsten P; Jansen KU
    Vaccine; 2011 Sep; 29(41):7207-11. PubMed ID: 21689707
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A longitudinal study of streptococcus pneumoniae carriage in healthy children in the 13-valent pneumococcal conjugate vaccine era.
    Mameli C; Fabiano V; Daprai L; Bedogni G; Faccini M; Garlaschi ML; Penagini F; Dilillo D; Torresani E; Gramegna M; Zuccotti GV
    Hum Vaccin Immunother; 2015; 11(4):811-7. PubMed ID: 25751237
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against vaccine serotype pneumococcal pneumonia in adults: A case-control test-negative design study.
    Lawrence H; Pick H; Baskaran V; Daniel P; Rodrigo C; Ashton D; Edwards-Pritchard RC; Sheppard C; Eletu SD; Litt D; Fry NK; Rose S; Trotter C; McKeever TM; Lim WS
    PLoS Med; 2020 Oct; 17(10):e1003326. PubMed ID: 33095759
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effectiveness of Pneumococcal Conjugate Vaccines of Different Valences Against Invasive Pneumococcal Disease Among Children in Taiwan: A Nationwide Study.
    Su WJ; Lo HY; Chang CH; Chang LY; Chiu CH; Lee PI; Lu CY; Hsieh YC; Lai MS; Lin TY
    Pediatr Infect Dis J; 2016 Apr; 35(4):e124-33. PubMed ID: 26974752
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dynamics of pneumococcal carriage among day-care center attendees during the transition from the 7-valent to the higher-valent pneumococcal conjugate vaccines in Greece.
    Grivea IN; Priftis KN; Giotas A; Kotzia D; Tsantouli AG; Douros K; Michoula AN; Syrogiannopoulos GA
    Vaccine; 2014 Nov; 32(48):6513-20. PubMed ID: 25252194
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.